Patent Assignment
Reel/Frame 038742/0673
Corrective Assignment to Correct the Conveying Party Data Previously Recorded on Reel 036130 Frame 0285. Assignor(S) Hereby Confirms the Merger and Change of Name.
Recorded: 2016-05-18
Pages: 10
Assignee
PHARMACYCLICS LLC
995 EAST ARQUES AVENUE, SUNNYVALE, CALIFORNIA, 94085
Covered Properties
(124)
Sapphyrins, Derivatives and Syntheses
Patent:
5,159,065 →
Application:
07/454,298 →
Photodynamic Activity of Sapphyrins
Patent:
5,120,411 →
Application:
07/454,301 →
Zeolite-Enclosed Transistion and Rare Earth Metal Ions as Contrast Agents for the Gastrointestinal Tract
Patent:
5,122,363 →
Application:
07/624,106 →
Metal Complexes of Water Soluble Texaphyrins
Patent:
5,252,720 →
Application:
07/822,964 →
Water Soluble Texaphtrin Metal Complex Preparation
Patent:
5,569,759 →
Application:
08/098,514 →
Water Soluble Texaphyrin Metal Complexes for Viral Deactivation
Patent:
5,432,171 →
Application:
08/100,093 →
Metal Complexes of Water Soluble Texaphyrins
Patent:
5,475,104 →
Application:
08/112,786 →
Soluble Texaphrin Metal Complexes for Singlet Oxygen Production
Patent:
5,439,570 →
Application:
08/112,871 →
Metal Complexes of Water Soluble Texaphyrins
Patent:
5,451,576 →
Application:
08/112,872 →
Hydroxylated Texaphyrins
Patent:
5,457,183 →
Application:
08/135,118 →
Texaphyrin Metal Complexes Having Improved Functionalization
Patent:
5,599,923 →
Application:
08/196,964 →
Reduced SP3 Texaphyrins
Patent:
5,504,205 →
Application:
08/280,351 →
Fluorescence Spectroscopy of Texaphyrins
Patent:
5,525,325 →
Application:
08/302,061 →
Radiation Sensitization Using Texaphyrins
Patent:
5,622,946 →
Application:
08/437,968 →
Method of Magnetic Resonance Image Enhancement
Patent:
5,580,543 →
Application:
08/458,267 →
Methods of Pruducing Singlet Oxygen Using Compounds Having Improved Functionalization
Patent:
5,756,726 →
Application:
08/468,935 →
Rna Photocleavage Using Texaphyrins
Patent:
5,714,328 →
Application:
08/484,551 →
Fluoresence Detection Using Texaphyrins
Patent:
5,632,970 →
Application:
08/486,967 →
Treatment of Neoplastic Tissue by Water-Soluble Texaphyrine Metal Complexes
Patent:
5,733,903 →
Application:
08/679,162 →
Metal Complexes of Texaphyrins.
Patent:
5,801,229 →
Application:
08/713,701 →
Radiation Sensitization Using Texaphyrins
Patent:
5,888,997 →
Application:
08/795,393 →
Metallation of Macrocycles with 2,4-Dicarbonyl-Metal Complexes
Patent:
5,886,173 →
Application:
08/903,121 →
Photodynamic Therapy of Pigment-Related Lesions
Patent:
5,775,339 →
Application:
08/914,272 →
Pharmaceutical Compositions Comprising Texaphyrins
Patent:
6,069,140 →
Application:
08/970,864 →
Water Soluble Texaphyrin Metal Complex Preparation
Patent:
5,994,535 →
Application:
09/031,239 →
Conjugates of Texaphyrins
Patent:
6,072,038 →
Application:
09/104,870 →
Use of Texaphyrin in Ocular Diagnosis and Therapy
Patent:
6,270,749 →
Application:
09/329,720 →
Meso-oxygenated texaphyrin analogues
Application:
10/310,592 →
Process for affecting neurologic progression
Application:
10/318,659 →
Publication:
US 2003/0130252
Assay for measuring acetylation or deacetylation activity of an enzyme
Application:
10/360,534 →
Publication:
US 2004/0091951
Texaphyrin Coordination Compounds and Uses Thereof
2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors
Application:
10/940,001 →
Publication:
US 2005/0176797
Process for inhibiting cell proliferation
Application:
11/040,542 →
Publication:
US 2005/0196466
Method and apparatus for disconnecting an external data storage device from a computer
Application:
11/111,181 →
Publication:
US 2006/0242362
High-purity texaphyrin metal complexes
Application:
11/235,475 →
Publication:
US 2007/0072838
Storage system for texaphyrin pharmaceutical formulations
Application:
11/241,549 →
Publication:
US 2007/0078119
Motexafin lutetium phototherapy with low fluences for treating vascular inflammation
Application:
11/267,104 →
Publication:
US 2006/0100190
Methods of Treating Cancer Using Hypofractionated Radiation and Texaphyrins
Application:
11/276,827 →
Publication:
US 2007/0219174
System and method for analysis of neurological condition
Application:
11/313,535 →
Publication:
US 2006/0136806
Method for treating neurologic diseases
Application:
11/337,187 →
Publication:
US 2006/0160784
Inhibitors of Tyrosine Kinases and Uses Thereof
Water-Soluble Zinc Ionophores, Zinc Chelators, and/or Zinc Complexes and Use for Treating Cancer
Novel Hydroxamates as Therapeutic Agents
Application:
11/830,686 →
Publication:
US 2007/0293540
Uses of Selective Inhibitors of HDAC8 for Treatment of Inflammatory Conditions
Application:
11/940,232 →
Publication:
US 2011/0150825
Acetylene Derivatives as Inhibitors of Histone Deacetylase
Application:
12/027,903 →
Publication:
US 2008/0139547
Thiohydroxamates as Inhibitors of Histone Deacetylase
Application:
12/140,034 →
Publication:
US 2009/0023798
2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors
Application:
12/255,540 →
Publication:
US 2009/0054432
Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
Application:
12/429,996 →
Publication:
US 2009/0270497
Inhibitors of Bruton's Tyrosine Kinase
Application:
12/499,008 →
Publication:
US 2010/0022561
Inhibitors of Bruton's Tyrosine Kinase
Application:
12/727,703 →
Publication:
US 2010/0324050
Texaphyrin solutions and pharmaceutical formulations
Application:
12/939,780 →
Publication:
US 2011/0046100
Inhibitors of Bruton's Tyrosine Kinase
Application:
13/162,449 →
Publication:
US 2011/0281322
Uses of Selective Inhibitors of HDAC8 for Treatment of Inflammatory Conditions
Application:
13/668,170 →
Publication:
US 2013/0078215
Manufacture, Compositions and Uses of Coagulation Factor Viia Modulator
Application:
13/954,088 →
Non-symmetric tripyrranes in the synthesis of novel macrocycles
Application:
60/229,247 →
Novel metallotexaphyrin derivatives
Application:
60/229,255 →
Agents for neutron capture therapy
Application:
60/229,366 →
Texaphyrin derivatives and their use for treating atheroma tumors and other neoplastic tissue
Application:
60/249,523 →
Compounds for Treating Atheroma Tumors and Other Neoplastic Tissue
Application:
60/304,197 →
In vitro and in vivo anti-tumor activity of sapphyrins
Application:
60/520,275 →
Process for inhibiting cell proliferation
Application:
60/549,324 →
Novel hydroxamates as therapeutic agents
Application:
60/560,108 →
Motexafin Lutetium phototherapy with low fluences for treating diffuse inflammation
Application:
60/625,477 →
System and method for analysis of neurological condition
Application:
60/638,798 →
Method for treating neurologic diseases
Application:
60/645,681 →
Methods and compositions for treating of cancer
Application:
60/737,601 →
Water-Soluble Zinc Ionophores, Zinc Chelators and/or Zinc Complexes and Use for Treating Cancer
Application:
60/743,588 →
Indole derivatives as inhibitors of histone deacetylase
Application:
60/783,287 →
Intracellular kinase inhibitors
Application:
60/801,074 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
60/826,720 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
60/828,590 →
Bruton's Tyrosine Kinase Activity Probe and Method of Using
Application:
60/864,350 →
Therapeutic Uses of Selective Inhibitors of HDAC8
Application:
60/865,825 →
Intracellular kinase inhibitors
Application:
60/869,664 →
Method of Using Histone Deacetylase Inhibitors and Monitoring Biomarkers in Combination Therapy
Application:
60/871,900 →
Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors
Application:
60/887,318 →
Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors
Application:
60/911,855 →
Therapeutic Uses of Selective Inhibitors of HDAC8
Application:
60/911,857 →
Therapeutic Uses of Selective Inhibitors of HDAC8
Application:
60/944,409 →
Thiohydroxamates as Inhibitors of Histone Deacetylase
Application:
60/944,425 →
Therapeutic Uses of Selective Inhibitors of HDAC8
Application:
60/954,777 →
Manufacture, Formulations and Uses of Coagulation Factor VIIa Inhibitor
Application:
60/980,386 →
Cysteine-Targeted Kinase Inhibitor Platform
Application:
61/017,125 →
Predicting Tumor Responsiveness with Apoptotic Agents and Calcium Flux Assay
Application:
61/026,023 →
Selective Inhibitors of Histone Deacetylase
Application:
61/045,198 →
Treatment of Non-Localized Inflammation with Pan-Hdac Inhibitors
Application:
61/047,565 →
Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
Application:
61/081,344 →
Oral Formulations of Histone Deacetylase Inhibitor
Application:
61/170,517 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
61/250,787 →
Methods of Treating Abc-Subtype of Diffuse Large B-Cell Lymphoma (Abc-Dlbcl) Using Inhibitors of Bruton's Tyrosine Kinase
Application:
61/351,130 →
METHODS OF USING INHIBITORS OF BRUTON'S TYROSINE KINASE IN THE DIAGNOSIS OF B-CELL LYMPHOPROLIFERATIVE DISORDERS (BCLDs)
Application:
61/351,655 →
Methods of Treating Non-Hodgkin Lymphoma Using Inhibitors of Bruton's Tyrosine Kinase
Application:
61/351,762 →
Btk Inhibitors for the Treatment of Immune Mediated Conditions
Application:
61/359,281 →
Methods of Treating Lymphocytic Leukemia Using Inhibitors of Bruton's Tyrosine Kinase
Application:
61/419,764 →
Methods of Treating Lymphocytic Leukemia Using Inhibitors of Bruton's Tyrosine Kinase
Application:
61/472,138 →
Methods and Compositions for Inhibition of Bone Resorption
Application:
61/502,271 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
61/507,482 →
Use of Inhibitors of Bruton's Tyrosine Kinase (Btk)
Application:
61/549,067 →
Method of administration for N-hydroxy-4-{2-[3-(N,N- dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide
Application:
61/573,585 →
Cinnamic Acid Hydroxyamides as Inhibitors of Histone Deacetylase 8
Application:
61/581,459 →
PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
Application:
61/582,199 →
Purinone Compounds as Kinase Inhibitors
Application:
61/593,146 →
Combinations of Histone Deacetylase Inhibitor and Pazopanib and Uses Thereof
Application:
61/600,491 →
Combinations of Histone Deacetylase Inhibitor and Pazopanib and Uses Thereof
Application:
61/602,544 →
Purinone Compounds as Kinase Inhibitors
Application:
61/637,765 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
61/647,956 →
Crystalline Forms of a Bruton's Tyrosine Kinase Inhibitor
Application:
61/655,381 →
Methods, Compositions and Uses for a CYS481 Mutation in BTK
Application:
61/675,303 →
Methods, Compositions and Uses for a CYS481 Mutation Btk
Application:
61/682,688 →
Methods, Assays, and Systems for Determining Protein Occupancy
Application:
61/712,675 →
Tec Family Kinase Inhibitor Adjuvant Therapy
Application:
61/722,107 →
Pyrrolopyrimidine Compounds as Kinase Inhibitors
Application:
61/727,031 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
61/769,103 →
Crystalline Forms of the Abexinostat Salt, a Process for Its Preparation and Pharmaceutical Compositions Containing It
Application:
61/772,191 →
Methods, Compositions and Uses for a CYS481 Mutation in Btk
Application:
61/780,652 →
Combinations of Bruton's Tyrosine Kinase Inhibitors and CYP3A4 Inhibitors
Application:
61/784,119 →
Methods for the Treatment of Solid Tumors
Application:
61/861,853 →
Methods for the Treatment of HER2 Amplified Cancer
Application:
61/865,059 →
Inhibitors of Bruton’S Tyrosine Kinase
Application:
61/884,888 →
Treatment Using Bruton’S Tyrosine Kinase Inhibitors and Immunotherapy
Application:
61/895,988 →
Methods for Delaying or Preventing the Onset of Type 1 Diabetes
Application:
61/905,081 →
Methods of Treating and Preventing Alloantibody Driven Chronic Graft Versus Host Disease
Application:
61/910,944 →
Methods of Treating and Preventing Graft Versus Host Disease
Application:
61/910,945 →
Inhibitors of Bruton's Tyrosine Kinase
Application:
61/912,483 →
Related Assignments
(5)
Other recorded transfers of the patents in this record — the chain of ownership.
Confirmatory License
May 20, 2008
From: UNIVERSITY OF TEXAS AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020972/0608 →
Merger
Jul 18, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036130/0254 →
Merger and Change of Name
Jul 18, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036130/0285 →
Corrective Assignment to Correct the Conveying Party Data Previously Recorded on Reel 036130 Frame 0254. Assignor(S) Hereby Confirms the Merger.
May 18, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038742/0624 →
Confirmatory License
Feb 12, 2025
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 070189/0994 →